AstraZeneca's stocks recently experienced several significant shifts. In 2024, it was among the healthcare stocks that tumbled, but analysts predict a significant comeback in 2025. Major investment brokers including
Morgan Stanley and
BofA have recommended buying AstraZeneca stocks, with a target price of
GBP145.00. Several financial bodies have recently acquired new holdings in AstraZeneca, including
New Republic Capital LLC and
Generate Investment Management Ltd. However, there have also been some selling movements, such as Moloney Securities Asset Management's sale of 4,504 shares.
China's probe into AstraZeneca has been a major concern yet updates seem to have reassured investors, driving a rise in stock prices. Major banks, including
Goldman Sachs,
UBS Group, and
Morgan Stanley, have revised AstraZeneca's stock rating and price targets. Finally, an
earnings miss of $0.05 EPS has been reported, with concerns noted over the risk of the Chinese probe. However, the FY2024
revenue report came in at $14.89B, with some analysts touting AstraZeneca as one of the most profitable pharmaceutical stocks of the moment.
AstraZeneca Stocks News Analytics from Tue, 10 Sep 2024 07:00:00 GMT to Sat, 15 Feb 2025 14:08:05 GMT -
Rating 3
- Innovation 4
- Information 7
- Rumor -4
